Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia

Inclusion Criteria:

Women and men ≥18 years of age
Body weight ≥50 kg.
Confirmed diagnosis of B cellNon-Hodgkin Lymphoma(according to World Health Organization [WHO] classification)including Chronic Lymphocytic Leukemia/Small cell Lymphocytic Leukemia (International Workshop),or Waldenstrom's Macroglobulinemia(Second International Workshop)
Have failed ≥1 previous treatment for B-NHL/CLL/WM, and have relapsed or refractory disease following last prior treatment.
Eastern Cooperative Oncology Group performance status of ≤ 2 and a life expectancy of at least 3 months.
Ability to swallow oral capsules without difficulty
Has recovered from adverse toxic effects of prior therapies

Meet the following clinical laboratory requirements:

Creatinine ≤ 1.5 × upper limit of normal (ULN)
Total bilirubin ≤ 1.5 x ULN
AST and ALT ≤ 3 × ULN
Platelet count ≥ 50,000/µL (non-hodgkin & Waldenstrom's)
Platelet count ≥ 30,000/µL (chronic lymphocytic leukemia)
Absolute Neutrophil count ≥ 1000/µL

Exclusion Criteria:

Prior allogeneic bone marrow transplant
Autologous stem cell transplant within 3 months of screening
Active central nervous system involvement
Subjects with autoimmune hemolytic anemia or immune thrombocytopenia
Prior treatment with a Btk inhibitor
Active uncontrolled infection
History of malabsorption
Uncontrolled illness, i.e cardiac, endocrine, respiratory, etc.
History of myocardial infarction, acute coronary syndromes, coronary angioplasty and/or stenting with in the previous 6 months
History of another currently active cancer
History of major surgery within 4 weeks or minor surgery within 1 week
Other medical or psychiatric illness or organ dysfunction
HIV positive
Positive for Hepatitis B surface antigen or Hepatitis C-virus